Sarcopenia and cognitive impairment in elderly women: Results from the EPIDOS cohort

Age and Ageing

Volumn 42, Issue 2, 2013, Pages 196-202

  Van Kan, Gabor Abellan ^a,b   Cesari, Matteo ^a,b   Gillette Guyonnet, Sophie ^a,b   Dupuy, Charlotte ^a,b   Nourhashémi, Fati ^a,b   Schott, Anne Marie ^c   Beauchet, Olivier ^d   Annweiler, Cédric ^d   Vellas, Bruno ^a,b   Rolland, Yves ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b Faculté de Médecine Centre Hospitalo universitaire   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Cognition; Cognitive decline; Community dwelling; Muscle mass; Older adults; Sarcopenia.; Women

Indexed keywords

ADL DISABILITY; AGE; AGED; ARTICLE; BODY COMPOSITION; COGNITIVE DEFECT; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EDUCATIONAL STATUS; FEMALE; GAIT; GAIT SPEED; GRIP STRENGTH; HUMAN; MUSCLE ATROPHY; PHYSICAL ACTIVITY; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; SHORT PORTABLE MENTAL STATUS QUESTIONNAIRE;

ABSORPTIOMETRY, PHOTON; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; BODY COMPOSITION; CHI-SQUARE DISTRIBUTION; COGNITION; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; GAIT; GERIATRIC ASSESSMENT; HAND STRENGTH; HUMANS; INDEPENDENT LIVING; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; MUSCLE STRENGTH DYNAMOMETER; NEUROPSYCHOLOGICAL TESTS; ODDS RATIO; PREVALENCE; QUESTIONNAIRES; RISK FACTORS; SARCOPENIA; SEX FACTORS;

EID: 84874529905     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afs173     Document Type: Article

References (38)

1. Burns JM, Johnson DK, Watts A et al. Reduced lean mass in early Alzheimer disease and its association with brain atrophy. Arch Neurol 2010; 67: 428-33.
2. Nourhashémi F, Andrieu S, Gillette-Guyonnet S et al. Is there a relationship between fat-free soft tissue mass and low cognitive function?. Results from a study of 7,105 women. J Am Geriatr Soc 2002; 50: 1796-801.
3. Auyeung TW, Kwok T, Lee J, Leung PC, Leung J, Woo J. Functional decline in cognitive impairment-the relationship between physical and cognitive function. Neuroepidemiology 2008; 31: 167-73.
4. Abellan van Kan G, Rolland Y, Gillette-Guyonnet S et al. Gait speed, body composition, and dementia. The EPIDOS-Toulouse Cohort. J Gerontol A Biol Sci Med Sci 2012; 67: 425-32.
5. Wirth R, Smoliner C, Sieber CC, Volkert D. Cognitive function is associated with body composition and nutritional risk of geriatric patients. J Nutr Health Aging 2011; 15: 706-10.
6. Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003; 88: 5766-72.
7. Llewellyn DJ, Lang IA, Langa KM, Melzer D. Vitamin D and cognitive impairment in the elderly US. population. J Gerontol A Biol Sci Med Sci 2011; 66: 59-65.
8. Schaap LA, Pluijm SM, Deeg DJ et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci 2009; 64: 1183-9.
9. Verghese J, Holtzer R, Oh-Park M, Derby CA, Lipton RB, Wang C. Inflammatory markers and gait speed decline in older adults. J Gerontol A Biol Sci Med Sci 2011; 66: 1083-9.
10. Reuben DB, Judd-Hamilton L, Harris TB, Seeman TE. The association between physical activity and inflammatory markers in high-functioning older persons. MacArthur Studies of Successful aging. J Am Geriatr Soc 2003; 51: 1125-30.
11. Licastro F, Pedrini S, Caputo L et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1 antichymotrypsin in patients with Alzheimer-s disease: peripheral inflammation or signals from the brain?. J Neuroimmunol 2000; 103: 97-102.
12. Zoico E, Rossi A, Di Francesco V et al. Adipose tissue infiltration in skeletal muscle of healthy elderly men: relationships with body composition, insulin resistance and, inflammation at the systemic and tissue level. J Gerontol A Biol Sci Med Sci 2010; 65A: 295-9.
13. Tezapsidis N, Johnston JM, Smith MA et al. Leptin: a novel therapeutic strategy for Alzheimer-s disease. J Alzheimers Dis 2009; 16: 731-40.
14. Lieb W, Beiser AS, Vasan RS et al. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 2009; 302: 2565-72.
15. Luchsinger JA, Gustafson DR. Adiposity and Alzheimer-s disease. Curr Opin Clin Nutr Metab Care 2009; 12: 15-21.
16. Yamagishi S, Nakamura K, Inoue H, Kikuchi S, Takeuchi M. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer-s disease. Med Hypotheses 2005; 64: 1205-7.
17. Dahl A, Hassing LB, Fransson E et al. Being overweight in midlife is associated with lower cognitive ability and steeper cognitive decline in late life. J Gerontol A Biol Sci Med Sci 2010; 65: 57-62.
18. Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci 2007; 30: 464-72.
19. Cesari M, Ferrini A, Zamboni V, Pahor M. Sarcopenia: current clinical and research issues. Open Geriatr Med J 2008; 1: 14-23.
20. Abellan van Kan G, Cameron Chumlea W, Gillette-Guyonet S et al. Clinical trials on sarcopenia: methodological issues regarding phase 3 trials. Clin Geriatr Med 2011; 27: 471-82.
21. Clark BC, Manini TM. Sarcopenia =/= dynapenia. J Gerontol A Biol Sci Med Sci 2008; 63: 829-34.
22. Abellan van Kan G, Rolland Y, Andrieu S et al. Systematic Review: gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people. An International Academy on Nutrition and Aging task force. J Nutr Health Aging 2009; 1313: 881-9.
23. Studenski S, Perera S, Patel K et al. Gait speed and survival in older adults. JAMA 2011; 305: 50-8.
24. Cooper R, Kuh D, Hardy R. Mortality Review Group; FALCon and HALCyon Study Teams. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. BMJ 2010; 341: c4467.
25. Dargent-Molina P, Favier F, Grandjean H et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet 1996; 348: 145-9.
26. Katz S, Ford A, Moskowitz R. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963; 185: 914-9.
27. Baumgartner RN, Koehler KM, Gallagher D et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147: 755-63.
28. Delmonico MJ, Harris TB, Lee JS et al. Health ABC Study Investigators. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc 2007; 55: 769-74.
29. Newman AB, Kupelian V, Visser M et al. Health ABC Study Investigators. Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc 2003; 51: 1602-9.
30. Morley JE, Abbatecola AM, Argiles JM et al. Society on Sarcopenia, Cachexia and Wasting Disorders Trialist Workshop. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc 2011; 12: 403-9.
31. Fielding RA, Vellas B, Evans WJ et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 2011; 12: 249-56.
32. Muscaritoli M, Anker SD, Argilés J et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) -cachexia-anorexia in chronic wasting diseases- and -nutrition in geriatrics-. Clin Nutr 2010; 29: 154-9.
33. Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412-23.
34. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 1975; 23: 433-41.
35. Erkinjuntti T, Sulkava R, Wikstrom J et al. Short portable mental status questionnaire as a screening test for dementia and delirium among the elderly. J Am Geriatr Soc 1987; 35: 412-6.
36. Abellan van Kan G. Epidemiology and consequences of sarcopenia. J Nutr Health Aging 2009; 13: 708-12.
37. Cesari M, Pahor M, Lauretani F et al. Skeletal muscle and mortality results from the InCHIANTI Study. J Gerontol A Biol Sci Med Sci 2009; 64: 377-84.
38. Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med 2006; 119: 526. e9-17.